Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
Clinical trial NCT04398914 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04398914
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-30
- Primary completion
- 2022-12-30
- Enrollment
- 216
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.